Arginine methylation patterns in LUAD: defining prognostic subtypes and relevance to immunotherapy.

Journal: Discover oncology
Published Date: May 21, 2025

Abstract

BACKGROUND: Lung cancer remains the leading cause of cancer-related death worldwide, with lung adenocarcinoma (LUAD) being the most common subtype. Arginine methylation, driven by protein arginine methyltransferases (PRMTs) has been connected to cancer biology, particularly in modulating cancer immunity. Thus, developing a PRMTs-related prognostic model might help create more personalized treatment plans for LUAD patients.

Authors

  • Qianyun Shen
    Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Yijie Yang
    Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Maoying Guan
    Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Hegen Li
    Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China. SPEDLA1@163.com.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals